Effect of Amphotericin B and Rifampin Against Coccidioides immitis In Vitro and In Vivo1

AUTOR(ES)

Huppert, M.

RESUMO

Amphotericin B, the principal drug used for treating systemic mycoses, possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule-endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B-rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.

Documentos Relacionados

• In Vitro Inhibition of Coccidioides Immitis Strains with Amphotericin B Plus Rifampin
• In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
• In Vitro and In Vivo Activities of Posaconazole against Coccidioides immitis
• Inhibition of Coccidioides immitis In Vitro and Enhancement of Anticoccidioidal Effects of Amphotericin B by Polymyxin B
• Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo.